GLPG250117P27500
- 1.40
- 0.000.00%
Galapagos Newsroom
Galapagos NV (AMS:GLPG) Stock Most Popular Amongst Retail Investors Who Own 56%, While Public Companies Hold 25%
Kepler Capital Remains a Sell on Galapagos (0JXZ)
Cautious Hold Rating for Galapagos: Unproven Efficacy and Logistical Concerns in CD19 CAR-T Programs
Galapagos Announced New Results From Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma; Demonstrated High Antitumor Activity And An Encouraging Safety Profile In All NHL Subtypes...
Galapagos' Innovative CAR T-Cell Therapy Shows Promise
Galapagos Downgraded to Reduce From Hold at Kepler Cheuvreux
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $31
Galapagos Third Quarter 2024 Earnings: €0.74 Loss per Share (Vs €0.39 Profit in 3Q 2023)
Galapagos Is Maintained at Sector Perform by RBC Capital
Galapagos Analyst Ratings
A Quick Look at Today's Ratings for Galapagos(GLPG.US), With a Forecast Between $26 to $31
Earnings Call: Galapagos Reports Solid Q3 Progress, Eyes IND Studies
Express News | Galapagos NV : RBC Cuts Target Price to $30 From $32
Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript Summary
6-K: Report of foreign private issuer (related to financial reporting)
Earnings Preview: Galapagos to Report Financial Results on October 30
Galapagos Reports 9M Results
Galapagos 9-Mos Rev EUR200.1M >GLPG.BT